A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory-Reference-Cited by-同舟云学术

A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory

Published:2014-11-05 Issue:261 Volume:6 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Swadling Leo¹,Capone Stefania²,Antrobus Richard D.¹³,Brown Anthony¹,Richardson Rachel¹,Newell Evan W.⁴⁵,Halliday John¹⁶,Kelly Christabel¹⁶,Bowen Dan¹,Fergusson Joannah¹,Kurioka Ayako¹,Ammendola Virginia²,Del Sorbo Mariarosaria²,Grazioli Fabiana²,Esposito Maria Luisa²,Siani Loredana²,Traboni Cinzia²,Hill Adrian¹³,Colloca Stefano²,Davis Mark⁴,Nicosia Alfredo²⁷⁸,Cortese Riccardo⁹,Folgori Antonella²,Klenerman Paul¹⁶,Barnes Eleanor¹³⁶

Affiliation:

1. Nuffield Department of Medicine, University of Oxford, Oxford OX1 3SY, UK.

2. ReiThera Srl (ex Okairos), Viale Città d’Europa 679, 00144 Rome, Italy.

3. The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.

4. Department of Microbiology and Immunology, Stanford University, Stanford, CA 94305, USA.

5. Singapore Immunology Network, Singapore 138648, Singapore.

6. National Institute for Health Research Oxford Biomedical Research Centre, and Translational Gastroenterology Unit, Oxford OX3 7LE, UK.

7. CEINGE, via Gaetano Salvatore 486, 80145 Naples, Italy.

8. Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Via S. Pansini 5, 80131 Naples, Italy.

9. Okairos AG, 4051 Basel, Switzerland.

Abstract

A prime-boost HCV vaccine strategy induces durable and broad T cell responses, characteristic of those associated with viral control.